Here are four takeaways:
1. Effective immediately, the new coding allows outpatient facilities and hospitals to receive reimbursement for using the DenerveX System to treat Facet Joint Syndrome in the spine.
2. Medovex’s system is in the final stages of development and is not commercially available yet.
3. The system is not CE-marked or FDA-cleared.
4. “The new reimbursement code in Germany is a significant milestone in our European launch preparation for the DenerveX System,” said Patrick Kullmann, president and COO, Medovex, “Germany is often recognized as a leader in early clinical adoption of new and cost effective technologies, being on the forefront of establishing reimbursement guidelines, and with other countries often following its lead.”
More articles on devices:
Vergenix STR receives positive final trial results — 5 highlights
Zacks Investment Research upgrades Cytori Therapeutics stock — 5 insights
Episurf Medical’s μifidelity platform reaches 100 case milestone: 3 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
